CLINICAL AND MOLECULAR CHARACTERISTICS OF KRAS-MUTANT STAGE IV NSCLC PATIENTS

Thị Yến Lê, Thị Lan Anh Đinh

Main Article Content

Abstract

Objectives: To describe the clinical and molecular characteristics of patients with stage IV non-small cell lung cancer (NSCLC) harboring KRAS mutations at K Hospital. Patients and method: A cross-sectional descriptive study was conducted on 147 patients with stage IV NSCLC confirmed to carry KRAS mutations by next-generation sequencing (NGS) at K Hospital, from January 2020 to December 2024. Results: The mean age was 61.8 years; 91.2% were male, and 82.3% had a history of smoking. Adenocarcinoma was predominant (93.2%), with most KRAS mutations located at codon 12, notably G12C (42.2%). Approximately 12.3% of patients harbored co-mutations, commonly STK11. Frequent metastatic sites included the contralateral lung, bone, pleura, and brain. Data on PD-L1 expression were limited. Conclusion: Stage IV NSCLC patients with KRAS mutations at K Hospital exhibited consistent clinical and molecular features, contributing to real-world data that may support prognosis and guide future personalized treatment approaches.

Article Details

References

Bray F, Laversanne M, Sung H, et al. Global cancer statistics 2022: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. NaN. 2024;(NaN):NaN-NaN. doi:10.3322/caac.21834
2. Rotow J, Bivona TG. Understanding and targeting resistance mechanisms in NSCLC. Nat Rev Cancer. 2017;17(11):637-658. doi:10.1038/ nrc.2017.84
3. Scagliotti GV, Parikh P, von Pawel J, et al. Phase III Study Comparing Cisplatin Plus Gemcitabine With Cisplatin Plus Pemetrexed in Chemotherapy-Naive Patients With Advanced-Stage Non–Small-Cell Lung Cancer. JCO. 2008;26(21): 3543-3551. doi:10.1200/JCO.2007. 15.0375
4. Gandhi L, Rodríguez-Abreu D, Gadgeel S, et al. Pembrolizumab plus Chemotherapy in Metastatic Non–Small-Cell Lung Cancer. New England Journal of Medicine. 2018;378(22):2078-2092. doi:10.1056/NEJMoa1801005
5. Hong DS, Fakih MG, Strickler JH, et al. KRASG12C Inhibition with Sotorasib in Advanced Solid Tumors. N Engl J Med. 2020;383(13):1207-1217. doi:10.1056/NEJMoa1917239
6. Riely GJ, Ou SHI, Rybkin I, et al. 99O_PR KRYSTAL-1: Activity and preliminary pharmacodynamic (PD) analysis of adagrasib (MRTX849) in patients (Pts) with advanced non–small cell lung cancer (NSCLC) harboring KRASG12C mutation. Journal of Thoracic Oncology. 2021;16(4): S751-S752. doi:10.1016/ S1556-0864(21)01941-9
7. Moore AR, Rosenberg SC, McCormick F, Malek S. RAS-targeted therapies: is the undruggable drugged? Nat Rev Drug Discov. 2020;19(8): 533-552. doi:10.1038/s41573-020-0068-6
8. Zheng D, Wang R, Zhang Y, et al. The prevalence and prognostic significance of KRAS mutation subtypes in lung adenocarcinomas from Chinese populations. Onco Targets Ther. 2016;9:833-843. doi:10.2147/OTT.S96834
9. Corral de la Fuente E, Olmedo Garcia ME, Gomez Rueda A, Lage Y, Garrido P. Targeting KRAS in Non-Small Cell Lung Cancer. Front Oncol. 2022;11:792635. doi:10.3389/fonc.2021.792635
10. Nguyễn Khánh Toàn, Ngô Văn Lâm, Phạm Thị Hường, và cộng sự. Đánh giá kết quả điều trị hóa chất trên bệnh nhân ung thư phổi không tế bào nhỏ giai đoạn IV có đột biến KRAS tại Bệnh viện Ung bướu Nghệ An. Tạp chí Y học Việt Nam. 2024; 542 (số chuyên đề): 91-100.